O6-methylguanine-DNA methyltransferase gene: Epigenetic silencing and prognostic value in head and neck squamous cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 6, 2004, Pages 967-975

  Zuo, Chunlai ^a   Ai, Lingbao ^a,b   Ratliff, Pam ^a   Suen, James Y ^a   Hanna, Ehab ^a   Brent, Thomas P ^c   Fan, Chun Yang ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; GUANINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ADULT; AGED; ARTICLE; DNA METHYLATION; DNA REPAIR; DNA SEQUENCE; EPIGENETICS; GENE INACTIVATION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; COMPARATIVE STUDY; DNA ADDUCT; ENZYMOLOGY; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PROMOTER REGION; RISK FACTOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA ADDUCTS; DNA METHYLATION; DNA REPAIR ENZYMES; GENE SILENCING; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK FACTORS; SURVIVAL ANALYSIS;

EID: 2942620221     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Weinberg RA. How cancer arises. Sci Am 1996;275:62-70.
3. Shields PG. Epidemiology of tobacco carcinogenesis. Curr Oncol Rep 2000;2:257-62.
4. Saffhill R, Margison GP, O'Connor PJ. Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta 1985;823:111-45.
5. 6 of guanine is only one of many chemical events that may initiate carcinogenesis. Cancer Invest 1984;2:233-8.
6. 6-methylguanine-DNA methyltransferase. J Biol Chem 1982;257:13776-80.
7. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 1985;145:1-16.
8. 6-alkylguanine-DNA methyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29.
9. Sukumar S, Notario V, Martin-Zanca D, Barbacid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 1983;306:658-61.
10. Tabin CJ, Bradley SM, Bargmann CI, et al. Mechanism of activation of a human oncogene. Nature 1982;300:143-9.
11. 6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinogenesis 2003;36:23-31.
12. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001;61:4689-92.
13. 6-methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001;61:8113-7.
14. 6-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001;92:2760-8.
15. 6methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
16. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. In: PA Jones, Vogt PK, editors. DNA methylation and cancer. New York: Springer-Verlag; 2000. p. 35-50.
17. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 2003;22:461-6.
18. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
19. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest 2003;83:519-26.
20. Matsukura S, Soejima H, Nakagawachi T, et al. CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer 2003;88:521-9.
21. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193-8.
22. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
23. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002;94:26-32.
24. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
25. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
26. 6-methylguanine-DNA methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939-42.
27. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 2002;8:131-7.
28. Wong TS, Tang KC, Kwong DL, et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int J Oncol 2003;22:869-74.
29. Viswanathan M, Tsuchida N, Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 2003;105:41-6.
30. Liu K, Zuo C, Luo QK, Suen JY, Hanna E, Fan CY. Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol 2003;12:50-6.
31. Fan C, Liu KL, Huang HY, et al. Frequent allelic imbalance and loss of protein expression of the DNA repair gene hOGG1 in head and neck squamous cell carcinoma. Lab Invest 2001;81:1429-38.
32. Liu KL, Huang HY, Mukunyadzi P, Suen J, Hanna E, Fan CY. Promoter hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2002;126:548-53.
33. 6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc Natl Acad Sci USA 1993;90:6468-72.
34. 6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res 1994;54:4648-52.
35. Sakumi K, Shiraishi A, Shimizu S, Tsuzuki T, Ishikawa T, Sekiguchi M. Methylnitrosourea-induced tumorigenesis in MGMT gene knock-out mice. Cancer Res 1997;57:2415-8.
36. Iwakuma T, Sakumi K, Nakatsuru Y, et al. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis 1997;18:1631-5.
37. 6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann Surg Oncol 2001;8:808-16.
38. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
39. 6-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int J Oncol 2002;21:1125-31.
40. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 2003;9:223-7.
41. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176-84.
42. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
43. Kawate H, Sakumi K, Tsuzuki T, et al. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci USA 1998;95:5116-29.
44. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5.
45. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.